XLONFUM
Market cap120mUSD
Jan 03, Last price
31.88GBP
1D
1.43%
1Q
-2.06%
Jan 2017
-43.00%
IPO
-56.96%
Name
Futura Medical PLC
Chart & Performance
P/E
—
P/S
3,122.28
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
17.97%
Rev. gr., 5y
0.00%
Revenues
3m
Net income
-7m
L+11.40%
CFO
570k
P
Earnings
Apr 08, 2025
Profile
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 3,101 | ||||||||
Cost of revenue | 10,065 | 6,896 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (6,964) | (6,896) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (379) | (1,025) | |||||||
Tax Rate | |||||||||
NOPAT | (6,585) | (5,871) | |||||||
Net income | (6,513) 11.40% | (5,846) 17.93% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 4,550 | 170 | |||||||
BB yield | -5.92% | -0.12% | |||||||
| Debt | |||||||||
Debt current | (432) | ||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 316 | ||||||||
Net debt | (7,714) | (4,458) | |||||||
| Cash flow | |||||||||
Cash from operating activities | 570 | (5,775) | |||||||
CAPEX | (1,506) | (741) | |||||||
Cash from investing activities | (1,434) | (741) | |||||||
Cash from financing activities | 4,550 | 170 | |||||||
FCF | (7,911) | (6,587) | |||||||
| Balance | |||||||||
Cash | 7,714 | 4,026 | |||||||
Long term investments | |||||||||
Excess cash | 7,559 | 4,026 | |||||||
Stockholders' equity | (66,744) | (62,978) | |||||||
Invested Capital | 72,221 | 67,121 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 301,406 | 287,478 | |||||||
Price | 0.26 -50.20% | 0.51 30.28% | |||||||
Market cap | 76,859 -47.78% | 147,189 38.18% | |||||||
EV | 69,144 | 142,731 | |||||||
EBITDA | (6,833) | (6,871) | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||